Icon PLC (ICLR) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.47 per share a year ago. These figures ...

DUBLIN 18, Ireland (AP) — Icon PLC (ICLR) on Wednesday reported first-quarter earnings of $154.2 million. The Dublin 18, Ireland-based company said it had profit of $1.90 per share. Earnings ...

Icon Plc and Medpace are both CROs, but Icon focuses on large pharma with an aggressive M&A strategy, unlike Medpace's small biotech focus. Initially impressed by Icon's financials, we purchased ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the first quarter 2025 ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc ...

For more information, submit a form at ICON plc Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030. According ...

ICON PLC (ICLR) has garnered significant attention from Stock Target Advisor, positioning itself as a top pick due to a promising earnings outlook and attractive valuation. With a projected 16.7% ...

In a market that continues to challenge even the most stalwart companies, ICON Plc (ICLR) stock has marked a new 52-week low, dipping to $227.56. This latest price level reflects the ongoing ...

ICON PLC sees FY 2024 EPS of $13.90-$14.10 versus the analyst consensus of $15.06. ICON PLC sees FY 2024 revenue of $8.26B-$8.30B versus the analyst consensus of $8.51B. ICON PLC's stock price closed ...

DUBLIN, September 03, 2024--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc ...

Investors might want to bet on Icon PLC (ICLR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...